论文部分内容阅读
目的:探讨RA罕见亚型缓和性血清阴性对称性滑膜炎伴凹陷性水肿综合征（RS3PE）患者抗骨质疏松治疗的临床价值。方法:回顾性分析2011年2月至2019年8月共12例北京积水潭医院风湿免疫科经治的RS3PE患者的临床资料、骨密度、骨转换生化标志物及治疗转归，并复习相关文献。结果:12例RS3PE平均年龄（65±11）岁，其中≥60岁7例。8例患者的骨密度为重度骨质疏松，2例为骨量减低。9例患者骨代谢标志物25-羟维生素D3[25（OH）Dn 3]水平减低。10例患者治疗方案均为小剂量泼尼松和慢作用药物。n 结论:结合RS3PE患者大多数为老年人，骨密度以骨质疏松和骨量减低较为常见，多数患者维生素D缺乏，且需要应用激素治疗的特点，提示骨质疏松筛查及抗骨质疏松治疗在RS3PE患者的诊治中具有重要作用，建议临床医师予以重视。“,”Objective:To explore the clinical value of anti-osteoporosis therapy in patients with rare subtype of rheumatoid arthritis, recurrent seronegative symmetric synovitis with pitting edema syndrome (RS3PE).Methods:The clinical data, bone mineral density, biochemical markers and treatment outcomes of 12 RS3PE patients treated from February 2011 to August 2019 in the Department of Rheumatology and Immunology, Beijing Jishuitan Hospital were retrospectively analyzed, and the related literature were reviewed.Results:The average age of these 12 cases was (65±11) years old, including older than 60 years old in 7 cases. The bone density of 8 patients showed severe osteoporosis, and 2 patients had decreased bone mass. In 9 patients, the level of 25-hydroxyvitamin Dn 3 [25(OH)Dn 3] was reduced. The treatment plan for all 10 patients was low-dose prednisone and disease-modifying antirheumatic drugs (DMARDs).n Conclusion:The majority of patients with RS3PE are elderly, and osteoporosis and bone loss is common. Most patients have vitamin D deficiency but need to be treated with glucocorticoid and DMARDs. This suggests that screening for osteoporosis and anti-osteoporosis treatment plays an important role in management of RS3PE patients.